Apimeds Pharmaceuticals (APUS) said late Thursday it priced its initial public offering at $4 per share, offering 3.4 million shares for $13.5 million in gross proceeds.
The company said the shares would begin trading Friday on the NYSE under the ticker symbol 'APUS.'
Additionally, the company also said it granted underwriters a 45-day option to buy 506,250 more shares and issued warrants for up to 194,063 shares.
Proceeds will fund a phase III knee osteoarthritis trial, MS study, product manufacturing, and general operations, the company said, adding the offering is expected to close Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.